compounded injectable semaglutide | NextGenRx Compound Pharmacy GLP-1 Weight Loss- Compounded Semaglutide

Miura T, Kimura N, Nakamura J, et al

The ESSENCE trial will provide valuable data on the maintenance of histological benefits over 240 weeks of continuous treatment, but long-term extension studies and off-treatment follow-up protocols are needed to characterize rebound kinetics

Research has shown improvements in blood sugar regulation and other metabolic indicators

Options for managing tolerance include a brief dose reduction for 4 to 8 weeks ("drug holiday" at a lower dose, not complete cessation), lifestyle optimization to maximize the medication effect, evaluation for other contributing factors (thyroid function, cortisol, sleep quality, medication interactions), and consideration of adding a complementary compound to address specific aspects of the plateau

The most important data comes from a substudy of the phase 2, double-blind, placebo-controlled trial published in The Lancet Diabetes and Endocrinology